BiotechTube
Aequita Bioworks

Aequita Bioworks

Cambridge, United States· Est.
aequitabioworks.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6M

Overview

Founded in 2021 and based in Cambridge, USA, Aequita Bioworks is a private, pre-revenue biotech company with a dual focus on diagnostics and therapeutics. Its core offering is a proprietary, automated platform that accelerates critical quality control assays, beginning with rapid sterility testing for the compounding pharmacy market. Led by a team with backgrounds in AI, biotech research, and operations, the company is leveraging its platform to develop additional assay products and a novel biologic aimed at mitigating muscle loss during GLP-1 weight loss therapy.

MusculoskeletalMetabolic Disorders

Technology Platform

Proprietary automated, AI-driven assay platform for rapid pharmaceutical quality control testing, starting with sterility testing reduced from 14 days to 24 hours.

Funding History

1
Total raised:$6M
Seed$6M

Opportunities

The massive and growing market for GLP-1 drugs creates a direct need for adjunctive therapies to prevent muscle loss, representing a multi-billion dollar co-therapy opportunity.
Additionally, the global pharmaceutical quality control market is ripe for disruption with faster, automated testing solutions that can reduce costs and accelerate drug release.

Risk Factors

Key risks include the high technical and regulatory hurdle of gaining official compendial acceptance for its rapid sterility method as a replacement for the 14-day test.
The company also faces significant therapeutic development risk, as its muscle-sparing biologic is in early discovery, and execution risk from pursuing both diagnostics and therapeutics simultaneously as a young, resource-constrained startup.

Competitive Landscape

In rapid sterility testing, competitors include established players like bioMérieux (BACT/ALERT), Charles River Laboratories (Milliflex), and newer entrants developing rapid microbiological methods. For the muscle-sparing therapeutic, competition will come from large pharmaceutical companies (e.g., Novo Nordisk, Eli Lilly) developing next-generation GLP-1 combos and other biotechs targeting muscle anabolism or proteostasis.

More companies in Diagnostics & Precision Medicine →More companies in United States →